Brooke Nichols, PhD

Adjunct Assistant Professor, Global Health

Brooke Nichols
617.638.5234

Biography

Brooke Nichols, PhD, MSc, is an infectious disease mathematical modeller and health economist working on both transmission dynamics for pathogens such as SARS-CoV-2, HIV and tuberculosis as well as optimal resource allocation to minimize the impact of these pathogens on human health. She is currently the co-lead of the World Health Organization (WHO) and Foundation for Innovative New Diagnostics (FIND)’s Access to COVID-19 Tools Accelerator (ACT-A) SARS-CoV-2 diagnostics modelling consortium. The modelling consortium focuses on optimizing the use of rapid antigen testing for SARS-CoV-2 in low- and middle-income countries.

Dr. Nichols’ research team is a multi-continental group of quantitative scientists and modellers focused on bridging the gap between traditional clinical science, epidemiology, health economics, mathematical modelling and actionable implementation. Through the development of novel quantitative methods and repurposing of existing methods, they design cost-effective and implementable interventions and programmes aimed at the reduction of transmission, morbidity, and mortality of infectious diseases. Using these novel approaches, Dr. Nichols and team have successfully guided and advised on national and international policy related to HIV (pre-exposure prophylaxis, HIV self-testing, differentiated service delivery, viral load monitoring), tuberculosis (diagnostics, multi-drug resistant tuberculosis treatment regimens), and SARS-CoV-2 (diagnostic testing algorithms).

Education

  • Erasmus Universiteit Rotterdam, PhD
  • Erasmus Universiteit Rotterdam, PhD
  • University of Massachusetts Amherst, MS
  • Mount Holyoke College, BA

Publications

  • Published on 3/1/2024

    Chevalier JM, Hansen MA, Coskun E, Sy KTL, Drakes J, Dowling S, Williams A, Jenkins S, Amole C, Haimbe P, Mpasela F, Shakwelele H, Nichols BE. Cost-effectiveness of intervention combinations towards the elimination of vertical transmission of HIV in limited-resource settings: a mathematical modelling study. Lancet Glob Health. 2024 Mar; 12(3):e457-e466. PMID: 38365416.

    Read at: PubMed
  • Published on 2/27/2024

    Chevalier JM, Han AX, Hansen MA, Klock E, Pandithakoralage H, Ockhuisen T, Girdwood SJ, Lekodeba NA, de Nooy A, Khan S, Johnson CC, Sacks JA, Jenkins HE, Russell CA, Nichols BE. Impact and cost-effectiveness of SARS-CoV-2 self-testing strategies in schools: a multicountry modelling analysis. BMJ Open. 2024 Feb 27; 14(2):e078674. PMID: 38417953.

    Read at: PubMed
  • Published on 1/18/2024

    de Jong SPJ, Felix Garza ZC, Gibson JC, van Leeuwen S, de Vries RP, Boons GJ, van Hoesel M, de Haan K, van Groeningen LE, Hulme KD, van Willigen HDG, Wynberg E, de Bree GJ, Matser A, Bakker M, van der Hoek L, Prins M, Kootstra NA, Eggink D, Nichols BE, Han AX, de Jong MD, Russell CA. Determinants of epidemic size and the impacts of lulls in seasonal influenza virus circulation. Nat Commun. 2024 Jan 18; 15(1):591. PMID: 38238318.

    Read at: PubMed
  • Published on 12/2/2023

    Han AX, Hannay E, Carmona S, Rodriguez B, Nichols BE, Russell CA. Estimating the potential impact and diagnostic requirements for SARS-CoV-2 test-and-treat programs. Nat Commun. 2023 Dec 02; 14(1):7981. PMID: 38042923.

    Read at: PubMed
  • Published on 9/28/2023

    Songo J, Whitehead HS, Nichols BE, Makwaya A, Njala J, Phiri S, Hoffman RM, Dovel K, Phiri K, van Oosterhout JJ. Provider-led community antiretroviral therapy distribution in Malawi: Retrospective cohort study of retention, viral load suppression and costs. PLOS Glob Public Health. 2023; 3(9):e0002081. PMID: 37768889.

    Read at: PubMed
  • Published on 8/4/2023

    Dovel K, Balakasi K, Phiri K, Shaba F, Offorjebe OA, Gupta SK, Wong V, Lungu E, Nichols BE, Masina T, Worku A, Hoffman R, Nyirenda M. Effect of index HIV self-testing for sexual partners of clients enrolled in antiretroviral therapy (ART) programs in Malawi: A randomized controlled trial. PLoS Med. 2023 Aug; 20(8):e1004270. PMID: 37540649.

    Read at: PubMed
  • Published on 7/12/2023

    Dovel K, Balakasi K, Hubbard J, Phiri K, Nichols BE, Coates TJ, Kulich M, Chikuse E, Phiri S, Long LC, Hoffman RM, Choko AT. Identifying efficient linkage strategies for men (IDEaL): a study protocol for an individually randomised control trial. BMJ Open. 2023 Jul 12; 13(7):e070896. PMID: 37438067.

    Read at: PubMed
  • Published on 7/3/2023

    Meyer-Rath G, Hounsell RA, Pulliam JR, Jamieson L, Nichols BE, Moultrie H, Silal SP. The role of modelling and analytics in South African COVID-19 planning and budgeting. PLOS Glob Public Health. 2023; 3(7):e0001063. PMID: 37399174.

    Read at: PubMed
  • Published on 7/3/2023

    Popping S, Nichols BE, Appelman B, Biemond JJ, Vergouwe M, Rosendaal FR, van der Valk M, de Bree GJ, Wiersinga WJ, Birnie E. Health Outcomes and Cost-effectiveness of Monoclonal SARS-CoV-2 Antibodies as Pre-exposure Prophylaxis. JAMA Netw Open. 2023 Jul 03; 6(7):e2321985. PMID: 37410460.

    Read at: PubMed
  • Published on 7/1/2023

    Govathson C, Long LC, Russell CA, Moolla A, Pascoe S, Nichols BE. A modelling framework for translating discrete choice experiment results into cost-effectiveness estimates: an application to designing tailored and scalable HIV and contraceptive services for adolescents in Gauteng, South Africa. J Int AIDS Soc. 2023 Jul; 26(7):e26124. PMID: 37463870.

    Read at: PubMed

View 97 more publications: View full profile at BUMC

View all profiles